Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alsevalimab
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
FPA150 (alsevalimab) is a fully human monoclonal antibody that targets B7-H4, a transmembrane protein of the B7 family known to negatively regulate T cell function. B7-H4 is highly expressed in several cancers, including breast, ovarian, endometrial, and other gynecological tumors. FPA150 blocks the inhibitory effect of B7-H4 on T cells and enhances antibody-dependent cell-mediated cytotoxicity (ADCC), providing a dual mechanism of action aimed at both reversing immune suppression and directly killing tumor cells. It is being developed as an immuno-oncology therapy for advanced solid tumors that overexpress B7-H4. The drug was originally developed by Five Prime Therapeutics[1][2][6][8].
- Other names
- Anti-B7-H4 antibodyAnti-B-7-H4 antibodyAnti-B 7-H4 antibodyalsevalimab
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on alsevalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alsevalimab.